

# THERAPIES AND BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE



**PHM125A**  
**January 2013**

Willem Westra  
***Project Analyst***

ISBN: 0-89336-715-X

**bcc** | Research  
Market Forecasting

**BCC Research**  
**49 Walnut Park, Building 2**  
**Wellesley, MA 02481**  
**866-285-7215, 781-489-7301**  
**www.bccresearch.com**  
**Custom Reports: carol.laverty@bccresearch.com**

## TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	1
STUDY GOALS AND OBJECTIVES	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	1
INTENDED AUDIENCE	2
METHODOLOGY AND INFORMATION SOURCES	2
ANALYST CREDENTIALS	2
RELATED REPORTS	3
BCC ON-LINE SERVICES	3
DISCLAIMER	3
CHAPTER 2 SUMMARY	5
SUMMARY TABLE GLOBAL INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET, THROUGH 2017 (\$ MILLIONS)	5
SUMMARY FIGURE GLOBAL INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET, BY REGION, 2010-2017 (\$ MILLIONS)	5
CHAPTER 3 OVERVIEW	7
INFLAMMATORY BOWEL DISEASE	7
DEFINITION OF INFLAMMATORY BOWEL DISEASE	7
Crohn's Disease	7
Ulcerative Colitis	7
EPIDEMIOLOGY OF INFLAMMATORY BOWEL DISEASE	8
Incidence and Prevalence of Inflammatory Bowel Disease	9
TABLE 1 GLOBAL INCIDENCE RANGES FOR CROHN'S DISEASE AND ULCERATIVE COLITIS (PER 100,000)	9
TABLE 2 GLOBAL PREVALENCE OF CROHN'S DISEASE AND ULCERATIVE COLITIS	10
TABLE 3 GLOBAL INCIDENCE FOR CROHN'S DISEASE	11
TABLE 4 GLOBAL PREVALENCE FOR CROHN'S DISEASE	12
TABLE 5 GLOBAL INCIDENCE FOR ULCERATIVE COLITIS	13
TABLE 6 GLOBAL PREVALENCE FOR ULCERATIVE COLITIS	14
CURRENT TREATMENTS FOR INFLAMMATORY BOWEL DISEASE	15
TABLE 7 THERAPEUTIC OPTIONS FOR INFLAMMATORY BOWEL DISEASE	15
Symptom Management	16
Inflammation Reduction	16
Surgery	16
Surgery for Ulcerative Colitis	16
Surgery for Crohn's Disease	17
Alternative Therapies	17
Fecal Bacteriotherapy	17
Pre- and Probiotic Supplementation	17
Helminth Therapy	17
BIOMARKER DEFINITION	18
Biomarkers Types	18
Diagnostic Biomarkers	18
TABLE 8 DIAGNOSTIC BIOMARKER EXAMPLES	19

<b>TOPIC</b>	<b>PAGE NO.</b>
Prognostic Biomarkers	19
Predictive Biomarkers	19
<i>TABLE 9 PREDICTIVE BIOMARKER EXAMPLES</i>	20
Target-Engagement Biomarkers	20
Biomarkers for Inflammatory Bowel Disease	20
<i>TABLE 10 BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE</i>	21
<i>TABLE 11 PUBMED-INDEXED SCIENTIFIC PUBLICATIONS REGARDING INFLAMMATORY BOWEL DISEASE BIOMARKERS, 2002-2012</i>	21
<i>TABLE 12 OPEN CLINICAL TRIALS FOR CROHN'S DISEASE THERAPEUTICS BY LOCATION, 2012 (NUMBER OF TRIALS)</i>	22
<i>TABLE 13 OPEN CLINICAL TRIALS FOR ULCERATIVE COLITIS THERAPEUTICS BY LOCATION, 2012 (NUMBER OF TRIALS)</i>	23
CHAPTER 4 INFLAMMATORY BOWEL DISEASE PHYSIOLOGY	25
OVERVIEW	25
ANATOMY OF THE INTESTINES	25
Small Intestine	25
Large Intestine	25
BIOLOGICAL FUNCTION OF THE INTESTINES	26
INFLAMMATORY BOWEL DISEASE TYPES	26
Crohn's Disease	26
Epidemiology	26
Risk Factors	27
Symptoms	27
Classification	27
Physiology	27
Causes	27
Ulcerative Colitis	27
Epidemiology	27
Risk Factors	28
Symptoms	28
Classification	28
Severity	28
Other Inflammatory Bowel Disease Types	28
INFLAMMATORY BOWEL DISEASE DIAGNOSIS	29
Signs and Symptoms	29
Clinical Aspects of Inflammatory Bowel Disease	29
<i>TABLE 14 CLINICAL ASPECTS OF INFLAMMATORY BOWEL DISEASE SUBTYPES</i>	30
Clinical Conditions Associated with inflammatory Bowel Disease	30
Pyoderma Gangrenosum	30
Primary Sclerosing Cholangitis	31
Malnutrition, Limited Nutrient Absorption and Stunting	31
CLINICAL CALCULATION OF CROHN'S DISEASE ACTIVITY INDEX SCORE	31
<i>TABLE 15 FACTORS FOR CALCULATING THE CROHN'S DISEASE ACTIVITY INDEX SCORE</i>	32
CLINICAL CALCULATION OF HARVEY-BRADSHAW INDEX	33
<i>TABLE 16 FACTORS FOR CALCULATING THE HARVEY-BRADSHAW INDEX</i>	33
CLINICAL CALCULATION OF THE CROHN'S DISEASE ENDOSCOPIC INDEX SEVERITY	34
CALCULATION OF THE MAYO SCORE	34

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 17 FACTORS FOR CALCULATING THE MAYO SCORE</i>	34
INFLAMMATORY BOWEL DISEASE SEROLOGIES	35
<i>TABLE 18 INFLAMMATORY BOWEL DISEASE SEROLOGIES TO INFORM CLINICAL DIAGNOSES</i>	35
CAUSES OF INFLAMMATORY BOWEL DISEASE	36
Genetics of Inflammatory Bowel Disease	36
<i>TABLE 19 GENETIC LOCI IMPLICATED IN INFLAMMATORY BOWEL DISEASE</i>	36
NOD2	37
NOD2 Mutations	37
Environmental Risk Factors for Inflammatory Bowel Disease	38
<i>TABLE 20 ENVIRONMENTAL RISK FACTORS FOR INFLAMMATORY BOWEL DISEASE</i>	38
Stress as a Risk Factor for Inflammatory Bowel Disease	39
CHAPTER 5 INFLAMMATORY BOWEL DISEASE PRODUCT SEGMENTS	41
<i>TABLE 21 INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET SEGMENTATION</i>	41
NON-BIOLOGIC DRUGS FOR INFLAMMATORY BOWEL DISEASE	41
<i>TABLE 22 COMPETITOR ASSESSMENT OF THE MAJOR MARKETED INFLAMMATORY BOWEL DISEASE THERAPEUTICS, 2012</i>	41
<i>TABLE 23 GLOBAL REVENUE FOR INFLAMMATORY BOWEL DISEASE-SPECIFIC NON-BIOLOGIC DRUGS, THROUGH 2017 (\$ MILLIONS)</i>	42
<i>TABLE 24 GLOBAL MARKET SHARES FOR INFLAMMATORY BOWEL DISEASE-SPECIFIC NON-BIOLOGIC DRUGS, 2011 (\$ MILLIONS/%)</i>	43
ASACOL	43
PENTASA	44
ENTOCORT	44
LIALDA	45
SALOFALK	45
BIOLOGIC DRUGS FOR INFLAMMATORY BOWEL DISEASE	46
<i>TABLE 25 GLOBAL REVENUE FOR INFLAMMATORY BOWEL DISEASE BIOLOGIC DRUGS, THROUGH 2017 (\$ MILLIONS)</i>	46
<i>TABLE 26 GLOBAL MARKET SHARE FOR INFLAMMATORY BOWEL DISEASE-SPECIFIC BIOLOGIC DRUGS, 2011 (\$ MILLIONS)</i>	46
REMICADE	46
HUMIRA	47
CIMZIA	48
TYSABRI	48
GLOBAL MARKETS FOR INFLAMMATORY BOWEL DISEASE THERAPEUTICS	49
<i>TABLE 27 LEADING INTERNATIONAL MARKETS FOR INFLAMMATORY BOWEL DISEASE THERAPEUTICS, THROUGH 2017 (\$ MILLIONS)</i>	49
GLOBAL MARKETS	49
U.S.	49
<i>TABLE 28 U.S. MARKET FOR INFLAMMATORY BOWEL DISEASE DRUGS, THROUGH 2017 (\$ MILLIONS)</i>	50
Japan	50
<i>TABLE 29 JAPANESE INFLAMMATORY BOWEL DISEASE DRUG MARKET, THROUGH 2017 (\$ MILLIONS)</i>	50
EU5	51
<i>TABLE 30 EU5 INFLAMMATORY BOWEL DISEASE DRUG MARKET, THROUGH 2017 (\$ MILLIONS)</i>	51

<b>TOPIC</b>	<b>PAGE NO.</b>
Rest of the World	51
<i>TABLE 31 REST OF THE WORLD INFLAMMATORY BOWEL DISEASE DRUG MARKET, THROUGH 2017 (\$ MILLIONS)</i>	52
EMERGING THERAPIES FOR INFLAMMATORY BOWEL DISEASE	52
CROHN'S DISEASE	52
<i>TABLE 32 THERAPEUTIC PIPELINE FOR CROHN'S DISEASE THERAPIES</i>	52
<i>TABLE 33 CLINICAL TRIAL RESULTS FOR EMERGING THERAPIES FOR CROHN'S DISEASE</i>	53
TXCell	54
Centocor Ortho Biotech	54
Enzo	54
ChemoCentryx	55
Osiris Therapeutics	55
Schering	55
Protein Design Labs BioPharma	56
NPS Pharmaceuticals	56
ULCERATIVE COLITIS	56
<i>TABLE 34 THERAPEUTIC PIPELINE FOR ULCERATIVE COLITIS THERAPIES</i>	57
<i>TABLE 35 CLINICAL TRIAL RESULTS FOR EMERGING ULCERATIVE COLITIS THERAPIES, 2007-2012</i>	58
Millennium/Takeda	58
Lipid Therapeutics	58
Abbott	58
Santarus and Cosmo Pharmaceuticals	59
Hutchison Medipharma	59
SUMMARY OF PROMISING INFLAMMATORY BOWEL DISEASE DRUGS IN DEVELOPMENT	60
Monoclonal Antibodies	60
HuZAF (fontolizumab): Biogen Idec	60
Stelara (Ustekinumab): Johnson and Johnson	61
Vedolizumab (MLN02): Takeda	61
Simponi (Golimumab): Johnson and Johnson	61
Small Molecules	61
Tetomilast: Otsuka	61
Firategrast: GlaxoSmithKline	62
Other Therapies	62
Alicaforsen: Isis Pharmaceuticals	62
Alequel: Enzo	62
Nicotine and Bupropion	63
Mycobacterium Avium Subspecies Paratuberculosis Vaccine	63
EMERGING TECHNOLOGIES FOR INFLAMMATORY BOWEL DISEASE	63
CHAPTER 6 INFLAMMATORY BOWEL DISEASE RESEARCH AND DEVELOPMENT	66
CLINICAL GUIDELINES FOR MANAGING INFLAMMATORY BOWEL DISEASE	66
RECOMMENDATIONS FOR INITIAL TREATMENT OF CROHN'S DISEASE	66
RECOMMENDATIONS FOR MAINTENANCE OF REMISSION IN CROHN'S DISEASE	66
RECOMMENDATIONS FOR INITIAL TREATMENT OF ULCERATIVE COLITIS	67
RECOMMENDATIONS FOR MAINTENANCE OF REMISSION IN ULCERATIVE COLITIS	67
CURRENT THERAPIES FOR INFLAMMATORY BOWEL DISEASE	68

<b>TOPIC</b>	<b>PAGE NO.</b>
CROHN'S DISEASE TREATMENT	68
ULCERATIVE COLITIS TREATMENT	68
<i>TABLE 36 THERAPIES FOR INFLAMMATORY BOWEL DISEASE</i>	68
Anti-Diarrheals	69
<i>TABLE 37 ANTI-DIARRHEAL THERAPIES FOR INFLAMMATORY BOWEL DISEASE</i>	69
Class Description and Mechanism of Action	69
Dosing	69
Efficacy	69
Antibiotics	69
<i>TABLE 38 ANTIBIOTIC THERAPIES FOR INFLAMMATORY BOWEL DISEASE</i>	69
Class Description and Mechanism of Action	70
Dosing	70
Efficacy	70
Aminosalicylates	70
<i>TABLE 39 AMINOSALICYLATE THERAPIES FOR INFLAMMATORY BOWEL DISEASE</i>	70
Class Description and Mechanism of Action	70
Dosing	71
Efficacy	71
Corticosteroids	71
<i>TABLE 40 CORTICOSTEROID THERAPIES FOR INFLAMMATORY BOWEL DISEASE</i>	72
Class Description and Mechanism of Action	72
Dosing	72
Efficacy	73
Immunosuppressants	73
<i>TABLE 41 IMMUNOSUPPRESSANT THERAPIES FOR INFLAMMATORY BOWEL DISEASE</i>	73
Class Description and Mechanism of Action	73
Dosing	74
Biologics	74
<i>TABLE 42 BIOLOGIC THERAPIES FOR INFLAMMATORY BOWEL DISEASE</i>	75
Class Description and Mechanism of Action	75
Dosing	76
Efficacy	76
Clinical Trials for Inflammatory Bowel Disease Therapies	77
<i>TABLE 43 OPEN CLINICAL TRIALS FOR CROHN'S DISEASE THERAPEUTICS BY LOCATION, 2012 (TRIALS)</i>	77
<i>TABLE 44 OPEN CLINICAL TRIALS FOR ULCERATIVE COLITIS THERAPEUTICS BY LOCATION, 2012 (TRIALS)</i>	78
CHAPTER 7 BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE	80
<i>TABLE 45 PUBMED-INDEXED SCIENTIFIC PUBLICATIONS FOR INFLAMMATORY BOWEL DISEASE BIOMARKERS, 2002-2012</i>	80
INFLAMMATORY BOWEL DISEASE BIOMARKERS	80
SERUM BIOMARKERS	81
C-Reactive Protein	81
C-Reactive Protein in the Diagnosis of Inflammatory Bowel Disease	82
C-Reactive Protein in the Evaluation of Inflammatory Bowel Disease	82
Antibodies and Auto-Antibodies	82
<i>TABLE 46 SERUM INFLAMMATORY BOWEL DISEASE BIOMARKERS</i>	83

<b>TOPIC</b>	<b>PAGE NO.</b>
FECAL BIOMARKERS	83
<i>TABLE 47 FECAL INFLAMMATORY BOWEL DISEASE BIOMARKERS</i>	84
EMERGING BIOMARKERS	84
<i>TABLE 48 NOVEL INFLAMMATORY BOWEL DISEASE BIOMARKERS</i>	85
Metabolomic Inflammatory Bowel Disease Biomarkers	85
Gene-Expression Inflammatory Bowel Disease Biomarkers	86
CHAPTER 8 PATENT LANDSCAPE	88
INFLAMMATORY BOWEL DISEASE DIAGNOSTICS AND THERAPEUTICS INDUSTRY	88
IMPORTANT CONCEPTS	88
Priority Dates	88
Patent Cooperation Treaty	88
International Classification Codes	89
METHODOLOGY	89
<i>NOTABLE PATENTS IN THE INFLAMMATORY BOWEL DISEASE DIAGNOSTIC MARKET</i>	89
<i>TABLE 49 MAJOR PATENT HOLDERS IN THE INFLAMMATORY BOWEL DISEASE DIAGNOSTICS SPACE</i>	89
Prometheus Laboratories	90
<i>TABLE 50 PUBLISHED PATENTS FOR PROMETHUES LABORATORIES IN INFLAMMATORY BOWEL DISEASE, 2005-2012</i>	90
Exagen Diagnostics	90
<i>TABLE 51 PUBLISHED PATENTS FOR EXAGEN DIAGNOSTICS IN INFLAMMATORY BOWEL DISEASE, 2005-2012</i>	90
<i>TABLE 52 MAJOR PATENT HOLDERS IN THE INFLAMMATORY BOWEL DISEASE THERAPEUTICS SPACE</i>	91
<i>TABLE 53 PUBLISHED PATENTS FOR PFIZER IN INFLAMMATORY BOWEL DISEASE, 2005-2012</i>	91
<i>TABLE 54 PUBLISHED PATENTS FOR NOVARTIS IN INFLAMMATORY BOWEL DISEASE, 2005-2012</i>	92
<i>TABLE 55 PUBLISHED PATENTS FOR NOVARTIS IN INFLAMMATORY BOWEL DISEASE, 2005-2012</i>	93
CHAPTER 9 COMPANY PROFILES	95
COMPANIES IN THE INFLAMMATORY BOWEL DISEASE DIAGNOSTICS SPACE	95
<i>TABLE 56 INFLAMMATORY BOWEL DISEASE DIAGNOSTIC COMPANIES</i>	95
REVENUE PER EMPLOYEE	95
<i>TABLE 57 INFLAMMATORY BOWEL DISEASE DIAGNOSTIC COMPANIES BY REVENUE PER EMPLOYEE, 2011</i>	96
EXAGEN LABORATORIES INC.	96
GENETIC ANALYSIS SA	97
GLYCOMINDS LTD.	98
INDEX PHARMACEUTICALS AB	98
PROMETHEUS LABORATORIES INC.	99
QUEST DIAGNOSTICS	100
SYNEXA LIFE SCIENCES	101
COMPANIES IN THE INFLAMMATORY BOWEL DISEASE THERAPEUTICS SPACE	101
<i>TABLE 58 INFLAMMATORY BOWEL DISEASE THERAPEUTIC COMPANIES</i>	101

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 59 INFLAMMATORY BOWEL DISEASE DIAGNOSTIC COMPANIES BY REVENUE PER EMPLOYEE, 2011</i>	102
ABBOTT LABORATORIES	103
ASTRAZENECA PLC	103
BIOGEN IDEC	104
FERRING PHARMACEUTICALS	105
HUTCHISON MEDIPHARM	105
IRONWOOD PHARMACEUTICALS	106
JANSSEN BIOTECH INC	106
KYORIN PHARMACEUTICAL	107
MILLENNIUM PHARMACEUTICALS	107
MYLAN INC.	108
NEOVACS AG	109
NOVARTIS AG	110
OSIRIS THERAPEUTICS	110
PFIZER	111
SHIRE PHARMACEUTICALS	112
UNION CHIMIQUE BELGE, S.A.	112
WARNER CHILCOTT	113
MERGERS AND ACQUISITIONS: DIAGNOSTICS	113
<i>TABLE 60 SIGNIFICANT MERGERS AND ACQUISITIONS IN THE INFLAMMATORY BOWEL DISEASE DIAGNOSTIC MARKET, 2008-2012</i>	113
<i>TABLE 61 SIGNIFICANT VENTURE-CAPITAL DEALS IN THE INFLAMMATORY BOWEL DISEASE DIAGNOSTIC MARKET, 2004-2012 (\$ MILLIONS)</i>	114
<i>TABLE 62 SIGNIFICANT STRATEGIC ALLIANCES IN THE INFLAMMATORY BOWEL DISEASE DIAGNOSTIC MARKET, 2008-2012</i>	115
MERGERS AND ACQUISITIONS: THERAPEUTICS	115
<i>TABLE 63 SIGNIFICANT MERGERS AND ACQUISITIONS IN THE INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET, 2008-2012</i>	115
<i>TABLE 64 SIGNIFICANT VENTURE-CAPITAL DEALS IN THE INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET, 2008-2012 (\$ MILLIONS)</i>	116
<i>TABLE 65 SIGNIFICANT STRATEGIC ALLIANCES IN THE INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET, 2008-2012</i>	116
CHAPTER 10 MARKET FACTORS	118
STRENGTH, WEAKNESS, OPPORTUNITY AND THREAT ANALYSIS	118
<i>TABLE 66 STRENGTH, WEAKNESS, OPPORTUNITY AND THREAT ANALYSIS FOR THE GLOBAL INFLAMMATORY BOWEL DISEASE MARKET</i>	118
MARKET FACTORS	118
Market Drivers	119
Increasing Disease Incidence	119
Chronic Nature of the Disease	119
Increased Diagnostic Sensitivity	119
Novel Therapeutics	119
Market Restrictors	120
Cure for Inflammatory Bowel Disease	120
Murky Disease Etiology	120
Limitations of Novel Therapies	120



<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 11 APPENDIX DEFINITIONS	122
ANTIBODY	122
AUTOIMMUNE DISEASE	122
BIOLOGIC THERAPY	122
BOWEL	122
COMPANION DIAGNOSTIC	122
CLINICAL LABORATORY IMPROVEMENT AMENDMENT	123
CROHN'S DISEASE	123
CURRENT PROCEDURAL TERMINOLOGY	123
DIAGNOSTIC SENSITIVITY	123
DIAGNOSTIC SPECIFICITY	123
ILEUM	123
INCIDENCE	123
INFLAMMATORY BOWEL DISEASE	124
MICROBIOTA AND MICROBIOME	124
NUCLEOTIDE	124
PREVALENCE	124
SEROLOGY	124
SINGLE-NUCLEOTIDE POLYMORPHISM	124
TUMOR NECROSIS FACTOR ALPHA	124
ULCERATIVE COLITIS	125

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET, THROUGH 2017 (\$ MILLIONS)	5
TABLE 1 GLOBAL INCIDENCE RANGES FOR CROHN'S DISEASE AND ULCERATIVE COLITIS (PER 100,000)	9
TABLE 2 GLOBAL PREVALENCE OF CROHN'S DISEASE AND ULCERATIVE COLITIS	10
TABLE 3 GLOBAL INCIDENCE FOR CROHN'S DISEASE	11
TABLE 4 GLOBAL PREVALENCE FOR CROHN'S DISEASE	12
TABLE 5 GLOBAL INCIDENCE FOR ULCERATIVE COLITIS	13
TABLE 6 GLOBAL PREVALENCE FOR ULCERATIVE COLITIS	14
TABLE 7 THERAPEUTIC OPTIONS FOR INFLAMMATORY BOWEL DISEASE	15
TABLE 8 DIAGNOSTIC BIOMARKER EXAMPLES	19
TABLE 9 PREDICTIVE BIOMARKER EXAMPLES	20
TABLE 10 BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE	21
TABLE 11 PUBMED-INDEXED SCIENTIFIC PUBLICATIONS REGARDING INFLAMMATORY BOWEL DISEASE BIOMARKERS, 2002-2012	21
TABLE 12 OPEN CLINICAL TRIALS FOR CROHN'S DISEASE THERAPEUTICS BY LOCATION, 2012 (NUMBER OF TRIALS)	22
TABLE 13 OPEN CLINICAL TRIALS FOR ULCERATIVE COLITIS THERAPEUTICS BY LOCATION, 2012 (NUMBER OF TRIALS)	23
TABLE 14 CLINICAL ASPECTS OF INFLAMMATORY BOWEL DISEASE SUBTYPES	30
TABLE 15 FACTORS FOR CALCULATING THE CROHN'S DISEASE ACTIVITY INDEX SCORE	32
TABLE 16 FACTORS FOR CALCULATING THE HARVEY-BRADSHAW INDEX	33
TABLE 17 FACTORS FOR CALCULATING THE MAYO SCORE	34
TABLE 18 INFLAMMATORY BOWEL DISEASE SEROLOGIES TO INFORM CLINICAL DIAGNOSES	35
TABLE 19 GENETIC LOCI IMPLICATED IN INFLAMMATORY BOWEL DISEASE	36
TABLE 20 ENVIRONMENTAL RISK FACTORS FOR INFLAMMATORY BOWEL DISEASE	38
TABLE 21 INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET SEGMENTATION	41
TABLE 22 COMPETITOR ASSESSMENT OF THE MAJOR MARKETED INFLAMMATORY BOWEL DISEASE THERAPEUTICS, 2012	41
TABLE 23 GLOBAL REVENUE FOR INFLAMMATORY BOWEL DISEASE-SPECIFIC NON-BIOLOGIC DRUGS, THROUGH 2017 (\$ MILLIONS)	42
TABLE 24 GLOBAL MARKET SHARES FOR INFLAMMATORY BOWEL DISEASE-SPECIFIC NON-BIOLOGIC DRUGS, 2011 (\$ MILLIONS/%)	43
TABLE 25 GLOBAL REVENUE FOR INFLAMMATORY BOWEL DISEASE BIOLOGIC DRUGS, THROUGH 2017 (\$ MILLIONS)	46
TABLE 26 GLOBAL MARKET SHARE FOR INFLAMMATORY BOWEL DISEASE-SPECIFIC BIOLOGIC DRUGS, 2011 (\$ MILLIONS)	46
TABLE 27 LEADING INTERNATIONAL MARKETS FOR INFLAMMATORY BOWEL DISEASE THERAPEUTICS, THROUGH 2017 (\$ MILLIONS)	49
TABLE 28 U.S. MARKET FOR INFLAMMATORY BOWEL DISEASE DRUGS, THROUGH 2017 (\$ MILLIONS)	50
TABLE 29 JAPANESE INFLAMMATORY BOWEL DISEASE DRUG MARKET, THROUGH 2017 (\$ MILLIONS)	50
TABLE 30 EU5 INFLAMMATORY BOWEL DISEASE DRUG MARKET, THROUGH 2017 (\$ MILLIONS)	51
TABLE 31 REST OF THE WORLD INFLAMMATORY BOWEL DISEASE DRUG MARKET, THROUGH 2017 (\$ MILLIONS)	52
TABLE 32 THERAPEUTIC PIPELINE FOR CROHN'S DISEASE THERAPIES	52
TABLE 33 CLINICAL TRIAL RESULTS FOR EMERGING THERAPIES FOR CROHN'S DISEASE	53

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 34 THERAPEUTIC PIPELINE FOR ULCERATIVE COLITIS THERAPIES	57
TABLE 35 CLINICAL TRIAL RESULTS FOR EMERGING ULCERATIVE COLITIS THERAPIES, 2007-2012	58
TABLE 36 THERAPIES FOR INFLAMMATORY BOWEL DISEASE	68
TABLE 37 ANTI-DIARRHEAL THERAPIES FOR INFLAMMATORY BOWEL DISEASE	69
TABLE 38 ANTIBIOTIC THERAPIES FOR INFLAMMATORY BOWEL DISEASE	69
TABLE 39 AMINOSALICYLATE THERAPIES FOR INFLAMMATORY BOWEL DISEASE	70
TABLE 40 CORTICOSTEROID THERAPIES FOR INFLAMMATORY BOWEL DISEASE	72
TABLE 41 IMMUNOSUPPRESSANT THERAPIES FOR INFLAMMATORY BOWEL DISEASE	73
TABLE 42 BIOLOGIC THERAPIES FOR INFLAMMATORY BOWEL DISEASE	75
TABLE 43 OPEN CLINICAL TRIALS FOR CROHN'S DISEASE THERAPEUTICS BY LOCATION, 2012 (TRIALS)	77
TABLE 44 OPEN CLINICAL TRIALS FOR ULCERATIVE COLITIS THERAPEUTICS BY LOCATION, 2012 (TRIALS)	78
TABLE 45 PUBMED-INDEXED SCIENTIFIC PUBLICATIONS FOR INFLAMMATORY BOWEL DISEASE BIOMARKERS, 2002-2012	80
TABLE 46 SERUM INFLAMMATORY BOWEL DISEASE BIOMARKERS	83
TABLE 47 FECAL INFLAMMATORY BOWEL DISEASE BIOMARKERS	84
TABLE 48 NOVEL INFLAMMATORY BOWEL DISEASE BIOMARKERS	85
TABLE 49 MAJOR PATENT HOLDERS IN THE INFLAMMATORY BOWEL DISEASE DIAGNOSTICS SPACE	89
TABLE 50 PUBLISHED PATENTS FOR PROMETHUES LABORATORIES IN INFLAMMATORY BOWEL DISEASE, 2005-2012	90
TABLE 51 PUBLISHED PATENTS FOR EXAGEN DIAGNOSTICS IN INFLAMMATORY BOWEL DISEASE, 2005-2012	90
TABLE 52 MAJOR PATENT HOLDERS IN THE INFLAMMATORY BOWEL DISEASE THERAPEUTICS SPACE	91
TABLE 53 PUBLISHED PATENTS FOR PFIZER IN INFLAMMATORY BOWEL DISEASE, 2005-2012	91
TABLE 54 PUBLISHED PATENTS FOR NOVARTIS IN INFLAMMATORY BOWEL DISEASE, 2005-2012	92
TABLE 55 PUBLISHED PATENTS FOR NOVARTIS IN INFLAMMATORY BOWEL DISEASE, 2005-2012	93
TABLE 56 INFLAMMATORY BOWEL DISEASE DIAGNOSTIC COMPANIES	95
TABLE 57 INFLAMMATORY BOWEL DISEASE DIAGNOSTIC COMPANIES BY REVENUE PER EMPLOYEE, 2011	96
TABLE 58 INFLAMMATORY BOWEL DISEASE THERAPEUTIC COMPANIES	101
TABLE 59 INFLAMMATORY BOWEL DISEASE DIAGNOSTIC COMPANIES BY REVENUE PER EMPLOYEE, 2011	102
TABLE 60 SIGNIFICANT MERGERS AND ACQUISITIONS IN THE INFLAMMATORY BOWEL DISEASE DIAGNOSTIC MARKET, 2008-2012	113
TABLE 61 SIGNIFICANT VENTURE-CAPITAL DEALS IN THE INFLAMMATORY BOWEL DISEASE DIAGNOSTIC MARKET, 2004-2012 (\$ MILLIONS)	114
TABLE 62 SIGNIFICANT STRATEGIC ALLIANCES IN THE INFLAMMATORY BOWEL DISEASE DIAGNOSTIC MARKET, 2008-2012	115
TABLE 63 SIGNIFICANT MERGERS AND ACQUISITIONS IN THE INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET, 2008-2012	115
TABLE 64 SIGNIFICANT VENTURE-CAPITAL DEALS IN THE INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET, 2008-2012 (\$ MILLIONS)	116
TABLE 65 SIGNIFICANT STRATEGIC ALLIANCES IN THE INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET, 2008-2012	116

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 66 STRENGTH, WEAKNESS, OPPORTUNITY AND THREAT ANALYSIS FOR THE GLOBAL INFLAMMATORY BOWEL DISEASE MARKET	118

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET, BY REGION, 2010-2017 (\$ MILLIONS)	5